Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
NCT04194125
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
25
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
177Lu-DOTATOC
Sponsor
University of Warmia and Mazury
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]